Effects of Nelfinavir in HIV-1 Infected Children
Author Information
Author(s): Salvador Resino, Beatriz Larrú, Jose Bellón, Rosa Resino, Isabel de José, Marisa Navarro, Juan Antonio Léon, José Tomás Ramos, Ma José Mellado, Ma Ángeles Muñoz-Fernández
Primary Institution: Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario 'Gregorio Marañón', Madrid, Spain
Hypothesis
What are the effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children over a 3-year follow-up?
Conclusion
Nelfinavir is a safe drug with a good profile and can achieve an adequate response in children.
Supporting Evidence
- Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of follow-up.
- HIV-infected children who achieved undetectable viral load were less than 40% in each visit during follow-up.
- Virological failure at defined end-point was confirmed in 30 out of 42 patients.
- Overall adherence to HAART was >90% among all infants during the follow-up.
- Only baseline viral load was an important factor to predict viral load control during follow-up.
Takeaway
This study looked at how a medicine called nelfinavir helps kids with HIV. It found that nelfinavir is safe and helps kids get better.
Methodology
A multicentre prospective study involving 42 vertically HIV-infected children on HAART with nelfinavir, monitored every 3 months for viral load and CD4+ cell count.
Potential Biases
Potential bias due to the non-uniform approach regarding antiretroviral treatment in the background regimen.
Limitations
The study included only children with previous ART and did not measure therapeutic drug monitoring.
Participant Demographics
Children aged 0.5 to 16.1 years, with a mean age of 6.7 years; 38.1% male; 54.7% had AIDS diagnosis.
Statistical Information
P-Value
0.003
Confidence Interval
CI95%: 0.16; 0.68
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website